ArriVent BioPharma Ownership | Who Owns ArriVent BioPharma?


OverviewForecastFinancialsChart

ArriVent BioPharma Ownership Summary


ArriVent BioPharma is owned by 31.49% institutional investors, 3.13% insiders, and 65.38% retail investors. Hhlr advisors is the largest institutional shareholder, holding 12.81% of AVBP shares.

AVBP Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockArriVent BioPharma31.49%3.13%65.38%
SectorHealthcare Stocks 231.98%10.74%-142.72%
IndustryBiotech Stocks 381.47%10.55%-292.02%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Hhlr advisors4.48M12.81%$82.74M
Infinitum asset management3.87M11.05%$71.38M
Suvretta capital management3.70M10.58%$68.33M
Fmr3.41M9.73%$62.87M
Orbimed advisors3.03M8.65%$55.85M
Blackrock funding, inc. /de2.37M5.66%$47.74M
Octagon capital advisors lp1.97M5.63%$36.37M
Novo1.94M5.55%$35.83M
Sofinnova investments1.70M4.85%$31.31M
Vanguard group1.87M4.46%$37.61M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Infinitum asset management3.87M13.13%$71.38M
Octagon capital advisors lp1.97M5.51%$36.37M
Novo1.94M2.31%$35.83M
Hhlr advisors4.48M2.02%$82.74M
Suvretta capital management3.70M1.75%$68.33M
Sofinnova investments1.70M1.71%$31.31M
Rosalind advisors215.87K1.53%$4.34M
Orbimed advisors3.03M1.32%$55.85M
Fund 1 investments619.85K1.27%$11.44M
General catalyst group management1.49M0.91%$27.58M

Top Buyers

HolderShares% AssetsChange
Fmr3.41M0.00%1.35M
Infinitum asset management3.87M13.13%450.00K
Blackrock funding, inc. /de2.37M0.00%326.70K
Goldman sachs group742.53K0.00%310.59K
Suvretta capital management3.70M1.75%290.66K

Top Sellers

HolderShares% AssetsChange
Siren---700.00K
Cormorant asset management, lp---585.46K
Morgan stanley97.59K0.00%-294.43K
Hidden lake asset management lp314.04K0.74%-292.81K
Franklin resources---256.42K

New Positions

HolderShares% AssetsChangeValue
Rosalind advisors215.87K1.53%215.87K$4.34M
Jane street group103.25K0.00%103.25K$2.08M
Burkehill global management, lp100.00K0.10%100.00K$1.84M
Anson funds management lp99.89K0.17%99.89K$1.84M
Los angeles capital management40.30K0.00%40.30K$744.34K

Sold Out

HolderChange
Ifp advisors-1.00
Clearstead advisors-1.00
Montag a & associates-11.00
Principal securities-16.00
Parkside financial bank & trust-20.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 202580-25.23%13,197,905-65.78%310.37%46-26.98%2531.58%
Sep 30, 20251058.25%38,570,31714.70%1101.19%6326.00%18-40.00%
Jun 30, 20259615.66%33,618,96315.59%961.30%498.89%3042.86%
Mar 31, 20257-91.14%11,264,335-59.25%350.53%4-92.98%--100.00%
Dec 31, 20248120.90%28,465,9279.87%841.42%587.41%11266.67%

Recent Insider Transactions


DateNameRoleActivityValue
Dec 10, 2025HILLHOUSE INVESTMENT MANAGEMENT, LTD.-Sell$12.98M
Jan 30, 2024HILLHOUSE INVESTMENT MANAGEMENT, LTD.-Buy$10.00M
Jan 30, 2024ORBIMED ADVISORS LLC Buy$4.00M
Jan 30, 2024GORDON CARL L Buy$4.00M
Jan 30, 2024HEALY JAMES-Buy$8.00M

Insider Transactions Trends


DateBuySell
2026 Q1--
2025 Q4-1
2025 Q3--
2025 Q2--
2024 Q14-

AVBP Ownership FAQ


Who Owns ArriVent BioPharma?

ArriVent BioPharma shareholders are primarily institutional investors at 31.49%, followed by 3.13% insiders and 65.38% retail investors. The average institutional ownership in ArriVent BioPharma's industry, Biotech Stocks , is 381.47%, which ArriVent BioPharma falls below.

Who owns the most shares of ArriVent BioPharma?

ArriVent BioPharma’s largest shareholders are Hhlr advisors (4.48M shares, 12.81%), Infinitum asset management (3.87M shares, 11.05%), and Suvretta capital management (3.7M shares, 10.58%). Together, they hold 34.44% of ArriVent BioPharma’s total shares outstanding.

Does Blackrock own ArriVent BioPharma?

BlackRock is not among the top 10 institutional shareholders of ArriVent BioPharma.

Who is ArriVent BioPharma’s biggest shareholder by percentage of total assets invested?

Infinitum asset management is ArriVent BioPharma’s biggest shareholder by percentage of total assets invested, with 13.13% of its assets in 3.87M ArriVent BioPharma shares, valued at 71.38M$.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools